## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Print or Type Re	esponses	)												
1. Name and Address of Reporting Person * GOLDBERG DAVID C				2. Issuer Name and Ticker or Trading Symbol ENZO BIOCHEM INC [ENZ]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)Director 10% Owner					
(Last) (First) (Middle) C/O ENZO BIOCHEM INC, 527 MADISON AVE				3. Date of Earliest Transaction (Month/Day/Year) 06/02/2011					X Officer (give title below) Other (specify below)  VP CorpDev Pres Enz Clin Labs					
(Street) NEW YORK, NY 10022			4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	· ·													
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	f Code (Instr. 8)		4. Securities Acquire (A) or Disposed of (Instr. 3, 4 and 5)		of (D)			ollowing (s)	Ownership of Form:	7. Nature of Indirect Beneficial Ownership	
				Code	V	Amount	(A) or (D)	Price	(msu. 3 a	and 4)		or Indirect (I) (Instr. 4)		
Common Stoo \$0.01	ck, par	value	06/02/2011		A		10,000	A	(1)	123,934	(2)		D	
				Derivative Securit	ies Acquire	ed, Dis	sposed o	f, or Ben	eficiall	•	OMB con	trol numbe	r.	
Security (Instr. 3) Or Experience Deriv	version xercise e of vative	3. Transactio Date (Month/Day/	on 3A. Deemed Execution Da any	Derivative Securit e.g., puts, calls, wa 4. Transaction Code Year) (Instr. 8)	ies Acquire arrants, op 5. Number of Derivative Securities	ed, Distions,  6. Da	ained in orm dis sposed o	this for plays a of f, or Bendible securion isable in Date	m are currented and currented are currented	not requestly valid  y Owned  tle and ount of erlying		9. Number of Derivative Securities Beneficially Owned	of 10. Ownersh Form of Derivati Security	ove Ownership (Instr. 4)
Secu	ırity				Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			4)			Following Reported Transaction(s (Instr. 4)	Direct (I or Indire (I) (Instr. 4)	/	
				Code V	(A) (D)	Date Exerc	_	Expiratior Date	Title	Amount or Number of Shares				
Reportin	ıg O	wners			•									
				Relations	hips									
Reporting (	Owner !	Name /	1,007		•									

D C O N /	Relationships						
Reporting Owner Name / Address	Director	tor 0 Officer Officer		Other			
GOLDBERG DAVID C C/O ENZO BIOCHEM INC 527 MADISON AVE NEW YORK, NY 10022			VP CorpDev Pres Enz Clin Labs				

# **Signatures**

/s/ David C. Goldberg	06/06/2011			
**Signature of Reporting Person	Date			

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Reporting Person was granted 10,000 shares of restricted common stock, par value \$0.01 per share ("Common Stock"), of the Company on June 2, 2011 in connection with his service as an officer of the Company. The shares will vest in three equal annual installments, beginning on June 2, 2012.
- (2) Includes (i) 979 shares of Common Stock indirectly beneficially owned through the UGMA accounts of Mr. Goldberg's children, and (ii) 9,227 shares of Common Stock held in the Company's 401(k) plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.